Strategic collaboration enables customers to harness the value of data capture coupled with data quality oversight
Fort Lauderdale, FL, October 20, 2015 - OmniComm Systems, Inc. (OmniComm) (OTCQX: OMCM), a global leading provider of clinical data management technology, today announced a partnership with CluePoints, a leading software provider of risk-based monitoring (RBM) solutions for clinical trials. Under the partnership, the two companies will work together to deliver OmniComm's electronic data capture (EDC) technology and services integrated with CluePoints' RBM software, offering customers a best-in-class solution that couples data collection with complete oversight of data quality.
Meeting the challenges of clinical data oversight in the age of more complex and global clinical trials is increasingly difficult for sponsors. OmniComm’s outcomes orientated EDC solutions enhance data quality while reducing query rates. By bringing its solutions together with CluePoints' Central Statistical Monitoring (CSM) solution, which supports robust statistically driven RBM and quality assurance strategies, the two companies can offer customers a sophisticated way of collectively embedding data capture, analysis and visualization into their processes in a single step.
Steve Young, senior director of transformation services at OmniComm, comments, "We are delighted to partner with CluePoints. As a provider of leading edge EDC and RBM enablement technology and services, integrating their powerful RBM software with TrialMaster® EDC technology and our RBM enablement services helps us advance the use of our systems outside the periscope of data capture. Together we can provide an answer to the challenging questions of clinical data oversight, streamlining processes and helping our customers to improve their outcomes."
CluePoints’ CEO, FranÒ«ois Torche, said, "Collectively our customers are looking to harness the value of EDC technology coupled with analytics for RBM and data quality oversight. The integration of our services and solutions will mean that they can get the best out of both systems, providing them with reassurance that they are achieving the highest quality data possible." CluePoints and OmniComm will together present 'The RBM Roadshow', a special thought leadership event discussing the benefits derived from an integrated solution for EDC technology, targeted source data verification (SDV), and centralized analytics/key risk indicators (KRIs). The events will take place in Cambridge, MA on November 4th, Chicago on November 9th and San Francisco on November 10th, 2015. To find out more and register, visit http://offers.omnicomm.com/rbm-roadshow-series.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.